ClinicalTrials.gg
RecruitingNCT06902974SUN004Updated Jul 1, 2026

Psilocybin-Assisted Therapy for Sexual Assault-Related PTSD

A Phase 2 interventional study of Psilocybin 25 mg in Post Traumatic Stress Disorder and PTSD, sponsored by Sunstone Medical. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by Sunstone Medical · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic — 13 open to participants now, 16 under way, 3 of them phase 3. Psilocybin · Stress Disorders, Post-Traumatic.

Planned enrollment
5th of 20
70 · median 33
Started
2026
with 6 others
Phase 2
10 of 20
5 open now
Primary completion
2027-11
later than 9 of 15 live
Registered
13th of 20
by date

Among the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, this one is the 5th largest by planned enrollment, is one of 7 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 9 of the 15 other live ones, and was the 13th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

13 of the 20 studies testing psilocybin in Stress Disorders, Post-Traumatic are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing psilocybin in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).

03

Conditions studied

  • Post Traumatic Stress Disorder
  • PTSD

Keywords

  • PTSD
  • sexual assault
  • psilocybin
  • posttraumatic stress disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cisgender women who are at least 18 years old.
  • Meet , Fifth Edition (DSM-5) criteria for current PTSD secondary to sexual assault (i.e., index trauma is sexual assault that occurred 6 or more months in the past).
  • CAPS-5 score of 25 or higher at Baseline.
  • Are able to swallow pills.
  • Are willing to be driven home after the Dosing Session with a family member or caregiver or trusted transportation.
  • Are able to complete all protocol-required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.
  • If able to become pregnant (i.e., with uterus and associated reproductive organs, fertile, following menarche and until becoming unless permanently sterile), must have a highly sensitive negative pregnancy test at study entry and prior to the Dosing Session, and must agree to use adequate through 10 days after the Dosing Session if sexually active with a biologically male partner. Adequate birth control methods include intrauterine device (IUD), injected, implanted, intravaginal, or transdermal hormonal methods, abstinence, oral hormones plus a barrier contraception, vasectomized sole partner, or double barrier contraception. Two forms of contraception are required with any barrier method or oral hormones (i.e. condom plus diaphragm, condom or diaphragm plus spermicide, oral hormonal contraceptives plus spermicide or condom).
  • Must agree to inform the clinical investigators within 48 hours of any medical conditions and procedures.
  • Are proficient in speaking and reading English.
  • Agree to have all clinic visit sessions recorded to audio and/or video. Participants may opt out of the data analysis of the recordings.
  • Agree to the following lifestyle modifications: a light breakfast 2 to 3 hours before dosing is permitted, however, participants will refrain from caffeine and nicotine 2 hours prior to dosing sessions and at least 6 hours after dosing, abstain from alcohol for 24 hours prior to dosing, not enroll in any other interventional clinical studies during the duration of the study, be driven home after the Dosing Session, and commit to medication dosing, therapy, and study procedures.
  • Agree to refrain from beginning new medication and/or psychotherapy treatment.
  • Continued treatment with SSRIs will be permitted if participants have been on a stable dose for 3 months or longer prior to enrollment. However, participants must be tapered off of monoamine oxidase inhibitors (MAOIs) prior to dosing.

In addition, participants may remain in stable (> 3 months) psychotherapy.

  • May have well-controlled hypertension that has been successfully treated with anti-hypertensive medicines.
  • May have asymptomatic virus (HCV) that has previously undergone evaluation and treatment as needed.
  • May have alcohol or substance use disorder if participant is not in withdrawal or requiring detox. Participants must have a plan, agreed upon by the principal investigator or designated physician, to reduce use of alcohol or other substances and to manage symptoms without self-medicating. Enrollment will require that, in the judgment of the principal investigator or designated physician, the plan for decreasing substance use is realistic and has a good chance of succeeding in order to prevent substance use from impacting the safety or efficacy of the treatment.
  • May have a history of or current Diabetes Mellitus (Type 2) if additional screening measures rule out underlying cardiovascular disease, if the condition is judged to be stable on effective management, and with approval by the principal investigator or designated physician.
  • May have hypothyroidism if taking adequate and stable thyroid replacement medication.

Exclusion criteria

Exclusion Criteria:

  • Male
  • Condition impairing oral intake or digestive absorption.
  • Are not able to give adequate .
  • Significant suicide risk as defined by suicidal ideation with intend and a plan as endorsed on items 5 on the C-SSRS within the past 3 months
  • Have any current problem which, in the opinion of the principal investigator or designated physician, might interfere with participation.
  • Would present a serious risk to others as established through clinical interview and contact with treating therapist.
  • Have a history of, or a current primary, schizophrenia, schizoaffective disorder or any form of psychotic disorder, major depressive disorder with psychotic features, bipolar affective disorder type 1, or personality disorders.
  • Require ongoing concomitant therapy with a psychiatric medication with exceptions described below (see Section 6.6).
  • Have received Electroconvulsive Therapy (ECT) within 12 weeks of enrollment.
  • Have evidence or history of recent stroke (\< 6 months from signing of ICF), recent myocardial infarction (\< 6 months from signing of ICF), or arrhythmia within 1 year of signing the ICF.
  • Have evidence or history of significant (controlled or uncontrolled) hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, renal, gastrointestinal, immunocompromising, or neurological disease, including seizure disorder, or any other medical disorder judged by the investigator to significantly increase the risk of psilocybin administration.
  • Have uncontrolled hypertension using the standard criteria of the American Heart Association (values of 140/90 milligrams of Mercury [mmHg] or higher).
  • Abnormal and clinically significant results on vital signs, , or laboratory tests at screening and baseline
  • Have symptomatic liver disease.
  • Are pregnant, nursing, or able to become pregnant and are not practicing an effective means of if sexually active with a biologically male partner.
  • Have to any ingredient of the study drug.
  • Positive urine drug screen for illicit drugs or drugs of abuse prior to the Dosing Session. Any positive urine drug test will be reviewed with participants to determine the pattern of use and eligibility will be determined at the investigator's discretion.
  • Current enrollment in any drug or device study or participation in such within 30 days of screening.
  • Other personal circumstances and behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin or completion of clinical study procedures (e.g., active participation in legal proceedings).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Psilocybin-Assisted Therapy

    This is a Phase 2, single-center, fixed dose, open-label study to explore the efficacy, safety, and tolerability of a 25 mg dose of oral psilocybin with therapy in adult women participants with PTSD secondary to an index trauma of sexual assault. There is no comparator group.

    Drug: Psilocybin 25 mg

Interventions

  • DrugPsilocybinStudies of PsilocybinPsilocybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Single dose, 25mg psilocybin, encapsulated, oral administration

    Also known as: Psilocybin-assisted therapy

06

What researchers measure

Primary outcomes

  1. To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault

    Incidence and occurrence of treatment emergent adverse events (TEAEs) and SAEs from signing of Informed Consent Form (ICF) until the End of Study (EOS) Visit

    Time frame: Between ICF until End of Study (approx. 8 weeks from baseline)

  2. To assess the safety and tolerability of psilocybin-assisted therapy in adult participants with PTSD secondary to sexual assault

    Incidence of changes in suicidal ideation/behavior (measured using the C-SSRS) score at all visits from Baseline to End of Study Visit

    Time frame: Between Baseline to End of Study (approx. 8 weeks from baseline)

Secondary outcomes

  1. To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault

    Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score The CAPS is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to: Make current (past month) diagnosis of PTSD Make lifetime diagnosis of PTSD Assess PTSD symptoms over the past week In addition to assessing the 20 DSM-5 PTSD symptoms, questions target the onset and duration of symptoms, subjective distress, impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and specifications for the dissociative subtype (depersonalization and derealization). Scores can range from 0 (absent) - the respondent denied the problem or the respondent's report doesn't fit the DSM-5 symptom criterion" to 4 (extreme/incapacitating) "The respondent described a dramatic symptom, far above threshold.'

    Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)

  2. To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault

    Change in the PTSD Checklist (PCL-5) The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD. Interpretation of the PCL-5 should be made by a clinician. The PCL-5 can be scored in different ways: A total symptom severity score (range - 0-80) can be obtained by summing the scores for each of the 20 items. DSM-5 symptom cluster severity scores can be obtained by summing the scores for the items within a given cluster, i.e., cluster B (items 1-5), cluster C (items 6-7), cluster D (items 8-14), and cluster E (items 15-20). A provisional PTSD diagnosis can be made by treating each item rated as 2 = "Moderately" or higher as a symptom endorsed, then following the DSM-5 diagnostic rule which requires at least: 1 B item (questions 1-5), 1 C item (questions 6-7), 2 D items (questions 8-14), 2 E items (questions 15-20).

    Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)

  3. To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault

    Change in State-Trait Anxiety Inventory (STAI) The State-Trait Anxiety Inventory (STAI) is a commonly used measure of trait and state anxiety (Spielberger, Gorsuch, Lushene, Vagg, \& Jacobs, 1983). It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes. It also is often used in research as an indicator of caregiver distress (e.g., Greene et al., 2017, Ugalde et al., 2014). Form Y, its most popular version, has 20 items for assessing trait anxiety and 20 for state anxiety. State anxiety items include: "I am tense; I am worried" and "I feel calm; I feel secure." Trait anxiety items include: "I worry too much over something that really doesn't matter" and "I am content; I am a steady person." All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always"). Higher scores indicate greater anxiety.

    Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)

  4. To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault

    Change in Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR-16) total score The Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR16) is a 16-item self-report questionnaire used to assess the severity of depressive symptoms, with scores ranging from 0 to 27, indicating no to very severe depression.

    Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)

  5. To assess the efficacy of psilocybin-assisted therapy on symptoms of PTSD in adult participants with PTSD secondary to sexual assault

    Time to event measures: starting of antidepressant medication for any reason, starting medication for continuing PTSD or depressive symptoms, relapse from a previously recovered state (clinician judgement, supported by the PCL-5), and onset or worsening of any psychiatric symptoms. Participants who withdraw from the study will be censored from the time to event analysis.

    Time frame: From Baseline to End of Study (approx. 8 weeks from baseline)

  6. To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault

    Change from Baseline to EOS in the Sheehan Disability Scale (SDS) total score. The SDS is a brief, 5-item self-report tool that assesses functional impairment in work/school, social life, and family life. How to Score Total score 0-30 (0 unimpaired, 30 highly impaired) Work/school (0-10) Social life (0-10) Family life/home responsibilities (0-10 Scores of ≥5 on any of the 3 scales; high scores are associated with significant functional impairment.

    Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)

  7. To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault

    Change from Baseline to EOS in the EuroQoL-5 Dimension, 5 level Scale (EQ-5D-5L) total score The EuroQoL 5-Dimension, 5-level Scale (EQ-5D-5L) is a health-related quality of life (HRQoL) questionnaire that assesses health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 5-level scale for each dimension, ranging from no problems to extreme problems.

    Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)

  8. To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault

    Proportion of participants with clinical response in CAPS-5 total score from Baseline. Clinical response in CAPS-5 is defined in a reduction of 10 or more points.

    Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)

  9. To assess the effect of psilocybin-assisted therapy on quality of life and participant functional impairment in adult participants with PTSD secondary to sexual assault

    Proportion of participants achieving remission of PTSD symptoms as measured by the CAPS-5 following the Dosing Session. Clinical remission is defined as a Loss of Diagnosis plus a severity score \< 20.

    Time frame: From Baseline to End of Study (approx. 8 weeks from Baseline)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Data sharing not required

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's planned 18 months is below that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 30, 2025
StartActual
May 23, 2026
Primary completionEst.
Nov 2027
CompletionEst.
May 2028
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06902974
Lead sponsor
Sunstone Medical
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
May 23, 2026
Primary completion
Nov 2027 (estimated)
Completion
May 2028 (estimated)
Last update
Jul 1, 2026

Study contacts

Clinical Evaluation Team
Contact
clinical.specialists@sunstonetherapies.com
301-750-3401
Celia Leeks
Contact
celia.leeks@sunstonetherapies.com
301-750-3229
Manish Agrawal, MD, MSC
principal investigator · Sunstone Medical, PC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion